Modified Vaccinia Ankara-Bavarian Nordic or MVA-BN is indicated for active immunisation against smallpox, Mpox, and related orthopoxvirus infections and disease in all adults 18 years of age and older ...

Two recent studies reveal that the efficacy of Bavarian Nordic's Mpox vaccine significantly declines within 6-12 months ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities.

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

Gavi (the Global Alliance for Vaccines and Immunization) has entered an advance purchase agreement with Bavarian Nordic to ...

Social media users claim a vaccine approved for use against mpox could cause a smallpox outbreak, but the only thing ...

The Vaccine Alliance, Gavi, and Bavarian Nordic on Wednesday announced an Advance Purchase Agreement to secure 500,000 doses of the Modified Vaccinia Ankara-Bavarian Nordic.

In an emulated target trial, a single dose of modified vaccinia Ankara-Bavarian Nordic vaccine was moderately effective in ...

The rate of mpox infection in the vaccinated group was 0.09 for every 1,000 person-days as compared to 0.20 in the ...

The Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is approved for active immunization against smallpox, Mpox, and ...

A single dose of the Modified vaccinia Ankara-Bavarian Nordic (MVA-BN) was 58% effective in protecting again mpox infection, according to a new study published in BMJ.